Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 509 (1) , 249-254
Abstract
No abstract availableKeywords
Funding Information
- JSPS KAKENHI (JP17K15531)
This publication has 32 references indexed in Scilit:
- Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapyScientific Reports, 2017
- Epigenetically Active Drugs Inhibiting DNA Methylation and Histone DeacetylationCurrent Pharmaceutical Design, 2017
- Epigenetic therapy and chemosensitization in solid malignancyCancer Treatment Reviews, 2017
- Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitorsBMC Cancer, 2016
- Epigenetic therapy in gastrointestinal cancer: the right combinationTherapeutic Advances in Gastroenterology, 2016
- Inhibitors of Emerging Epigenetic Targets for Cancer Therapy: a Patent Review (2010–2014)Pharmaceutical Patent Analyst, 2015
- Epigenetic Therapy for Solid Tumors: from Bench Science to Clinical TrialsEpigenomics, 2015
- Different Effects of Epigenetic Modifiers on the Cytotoxicity Induced by 5-Fluorouracil, Irinotecan or Oxaliplatin in Colon Cancer CellsBiological and Pharmaceutical Bulletin, 2014
- Will Dna Methylation Inhibitors Work In Solid Tumors? A Review Of The Clinical Experience With Azacitidine And Decitabine In Solid TumorsEpigenomics, 2010
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004